Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report)'s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $3.34 and traded as high as $3.56. Voyager Therapeutics shares last traded at $3.54, with a volume of 406,199 shares.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on VYGR. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Voyager Therapeutics in a research report on Monday, July 13th. HC Wainwright reissued a "buy" rating on shares of Voyager Therapeutics in a research note on Thursday. Finally, Wall Street Zen cut Voyager Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $16.50.
View Our Latest Stock Analysis on Voyager Therapeutics
Voyager Therapeutics Stock Performance
The stock has a market capitalization of $218.13 million, a PE ratio of -1.97 and a beta of 1.31. The firm has a 50 day moving average of $3.34 and a 200-day moving average of $3.68.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.08. Voyager Therapeutics had a negative net margin of 312.63% and a negative return on equity of 57.92%. The business had revenue of $3.17 million for the quarter, compared to the consensus estimate of $4.52 million. On average, sell-side analysts predict that Voyager Therapeutics, Inc. will post -1.63 earnings per share for the current year.
Institutional Trading of Voyager Therapeutics
Several institutional investors have recently bought and sold shares of VYGR. AQR Capital Management LLC lifted its position in Voyager Therapeutics by 179.3% during the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company's stock worth $1,674,000 after buying an additional 317,927 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Voyager Therapeutics during the first quarter worth $218,000. Acadian Asset Management LLC boosted its stake in Voyager Therapeutics by 863.3% during the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company's stock worth $778,000 after acquiring an additional 206,758 shares during the last quarter. Geode Capital Management LLC boosted its stake in Voyager Therapeutics by 1.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company's stock worth $3,474,000 after acquiring an additional 11,929 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in Voyager Therapeutics by 5.1% in the second quarter. American Century Companies Inc. now owns 138,269 shares of the company's stock worth $430,000 after purchasing an additional 6,748 shares during the period. Institutional investors and hedge funds own 48.03% of the company's stock.
About Voyager Therapeutics
(
Get Free Report)
Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company's core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.
The firm's pipeline includes several AAV-based candidates in preclinical and early clinical development.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
